Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05277272

INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic Lymphohistiocytoses Clinical Trial

Official title:
INTO-HLH- Insight Into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): A Disease Registry for Patients With HLH

Clinical Trial Summary

The purpose of this observational study is to collect data on the natural history of disease of patients with Hemophagocytic Lymphohistiocytosis (HLH) including diagnosis, treatments, responses, and outcomes.

Clinical Trial Description

Hemophagocytic Lymphohistiocytosis (HLH) is a complex, hyperinflammatory syndrome resulting from the interplay of genetic predisposition and various environmental factors. Despite available treatment options for HLH, approximately 30% of patients do not respond to therapy. Moreover, the standard therapy is constrained by its toxicities, and safer treatments are pursued. There is an unmet need for a deeper understanding of the natural history, clinical/etiologic diversity, complications, and treatment outcomes of patients with HLH, specifically from North America. The proposed study, a collaboration between Cincinnati Children's Hospital Medical Center (CCHMC), Texas Children's Hospital, and Sobi Inc. aims to establish a robust registry that will enable investigators to better define the natural history of HLH. ;

Study Design

Related Conditions & MeSH terms

  • Hemophagocytic Lymphohistiocytoses
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT05277272
Study type Observational [Patient Registry]
Source Children's Hospital Medical Center, Cincinnati
Contact Michael Jordan, MD
Phone (513) 803-9063
Email Michael.Jordan@cchmc.org
Status Recruiting
Phase
Start date December 31, 2021
Completion date January 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05491304 - Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis Phase 4
Completed NCT05531721 - HLH Patients - a Retrospective Study
Not yet recruiting NCT05600959 - Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
Completed NCT03546101 - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting NCT05898477 - Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Recruiting NCT05882175 - Prospective Validation of the OHI Index
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Terminated NCT03985423 - A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Not yet recruiting NCT05677178 - Response Prediction in EBV-HLH Using Metabonomics Analysis
Recruiting NCT03117010 - Prospective Cohort for Adult Hemophagocytosis
Not yet recruiting NCT06160791 - Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Phase 2
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Completed NCT06047210 - Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
Not yet recruiting NCT05988177 - Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections N/A